Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Transanastomotic Tube Use and Anastomotic Stricture: A Multicenter Prospective Randomized Trial in Neonates Undergoing Repair of Type C Esophageal Atresia with Distal Tracheoesophageal Fistula.

Annals of surgery·2026

Same author

Incidence and Management Trends in Advanced Head and Neck Non-Melanoma Skin Cancer in Ontario.

Current oncology (Toronto, Ont.)·2026

Same author

Defining the Role of SABR in Head and Neck Cancer: Results From a Multi-institutional Delphi Consensus.

International journal of radiation oncology, biology, physics·2026

Same author

Psychosocial outcomes of velopharyngeal insufficiency treatment in patients with cleft palate: A systematic review.

Journal of plastic, reconstructive & aesthetic surgery : JPRAS·2026

Same author

Cognitive Groove community-based rehabilitation for older adults: study protocol for a multisite parallel randomized controlled trial.

Trials·2026

Same author

Advances in Epicardial Access for Ventricular Tachycardia Ablation: From Historical Techniques to Carbon Dioxide Insufflation.

Reviews in cardiovascular medicine·2026

Same journal

Intramedullary Spinal Cord Tumors.

Neurosurgery clinics of North America·2026

Same journal

Spinal Cord Deformities Associated with Intramedullary Spinal Cord Tumors.

Neurosurgery clinics of North America·2026

Same journal

Radiation Therapy for Spinal Cord Tumors.

Neurosurgery clinics of North America·2026

Same journal

Treatment Strategies of Intramedullary Spinal Cord Tumors.

Neurosurgery clinics of North America·2026

Same journal

Vascular Lesions of the Spinal Cord: Arteriovenous and Cavernous Malformations.

Neurosurgery clinics of North America·2026

Same journal

Hemangioblastomas of the Spinal Cord.

Neurosurgery clinics of North America·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Nov 11, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Brain Tumor Vaccines.

Justin Lee¹, Benjamin R Uy¹, Linda M Liau¹

¹UCLA Department of Neurosurgery, David Geffen School of Medicine at UCLA, University of California Los Angeles, 300 Stein Plaza Driveway Suite 420 Los Angeles, CA 90095, USA.

Neurosurgery Clinics of North America

|March 30, 2021

Summary

This summary is machine-generated.

Therapeutic cancer vaccines, including peptide and dendritic cell types, show promise for treating brain tumors by stimulating immune responses. These vaccines aim to generate antitumor T cells and antibodies capable of crossing the blood-brain barrier.

Keywords:

Brain tumor immunotherapy Brain tumor vaccines Dendritic cell vaccines Peptide vaccines

More Related Videos

Author Spotlight: Modeling Brain Tumors In Vivo Using Electroporation-Based Delivery of Plasmid DNA Representing Patient Mutation Signatures

Author Spotlight: Modeling Brain Tumors In Vivo Using Electroporation-Based Delivery of Plasmid DNA Representing Patient Mutation Signatures

Published on: June 23, 2023

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Related Experiment Videos

Last Updated: Nov 11, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Author Spotlight: Modeling Brain Tumors In Vivo Using Electroporation-Based Delivery of Plasmid DNA Representing Patient Mutation Signatures

Author Spotlight: Modeling Brain Tumors In Vivo Using Electroporation-Based Delivery of Plasmid DNA Representing Patient Mutation Signatures

Published on: June 23, 2023

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Area of Science:

Immunology
Oncology
Neuroscience

Background:

Brain tumors present unique challenges for treatment due to the blood-brain barrier.
Activating the immune system offers a potential strategy to target brain tumor antigens.

Purpose of the Study:

To review the potential of peptide and dendritic cell vaccines in combating brain tumors.
To highlight the mechanisms by which these vaccines stimulate systemic antitumor immunity.

Main Methods:

Investigation of recent clinical trials involving peptide vaccines targeting specific tumor antigens (e.g., EGFRvIII, survivin).
Analysis of studies using dendritic cell vaccines pulsed with various tumor-associated materials (peptides, mRNA, tumor lysate).

Main Results:

Vaccines induce systemic immune responses, including T cell activation and antibody production.
These immune components have the potential to penetrate the blood-brain barrier.

Conclusions:

Peptide and dendritic cell vaccines demonstrate significant therapeutic potential for brain tumor treatment.
Further research and clinical trials are warranted to establish these vaccines as a standard therapy.